Cepharanthin: Sikkerhed og effekt mod mild COVID-19
Cepharanthine (CEP), en naturlig behandling, hæmmer SARS-CoV-2 aktivitet effektivt in vitro og in vivo. I en dobbeltblind, randomiseret, placebo-kontrolleret undersøgelse blev effekten og sikkerheden af CEP evalueret hos voksne med asymptomatisk eller mild COVID-19 [source_link].
Studien omfattede 262 randomiserede deltagere, hvoraf 188 fuldførte forsøget. Deltagerne blev opdelt i tre grupper; en gruppe modtog 120 mg/dag CEP, en anden 60 mg/dag CEP, og den sidste gruppe fik placebo i 5 dage.
Det primære endepunkt var tiden fra randomisering til negativ nasopharyngeal podning, mens sikkerheden var et sekundært fokus. Analysen viste ingen signifikant forskel i tid til negativ test mellem grupperne. Dog viste 60 mg/dag CEP en tendens til hurtigere negativisering (median forskel på -0,77 dage, HR = 1,40, p = 0,072). Blandt deltagere med god medicinsk compliance viste 60 mg/dag CEP en signifikant forkortelse af tiden til negativ test (median forskel på -0,87 dage, HR = 1,56, p = 0,035). Der blev ikke registreret alvorlige bivirkninger i nogen af grupperne.
Dette er en AI-genereret oversættelse og opsummering. Læseren bør konsultere den originale kilde for validering og ikke træffe kliniske beslutninger udelukkende på baggrund af dette resumé.
#Intern medicin: infektionsmedicin #Intern medicin: gastroenterologi #Klinisk farmakologi
Læs hele studiet her: [source_link]
Læs hele studiet her: læs her
generer et html link ud fra Her er informationerne fra artiklen præsenteret i et struktureret format, som du kan bruge til at udfylde din kode:
### Reference
– **Titel:** Cepharanthine treatment for asymptomatic or mild COVID-19: A double-blind, randomized, placebo-controlled trial
– **Forfattere:** Jianyi Wei, Shupeng Liu, Yuexiang Bian, Lei Li, Biyun Qian, Zixuan Shen, Yan Zhang, Adila Abuduaini, Fuchen Dong, Xin Zhang, Jinhui Li, Yongpei Yu, Weituo Zhang, Jun Wang, Wei Zhai, Qixiang Song, Yu Zheng, Weihua Pan, Lanlan Yu, Qimin Zhan, Ning Zhang, Junhua Zheng, Shuming Pan, Chen Yao, Hai Li
– **Tidsskrift:** Scientific Reports
– **Udgivelsesdato:** 2025 Jan 31
– **Volumen:** 15
– **Udgave:** 1
– **Artikelnr.:** 3875
– **DOI:** [10.1038/s41598-024-75891-3](https://doi.org/10.1038/s41598-024-75891-3)
### Affiliations
1. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiaotong University School of Medicine), Shanghai, China.
2. Department of Otorhinolaryngology-Head & Neck Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
3. Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
4. Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China.
5. Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
6. Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
7. Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
8. Department of Respiratory Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
9. Department of Pediatric Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
10. Peking University – Yunnan Baiyao International Medical Research Center, Beijing, China.
11. Department of Emergency, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
12. Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China.
13. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiaotong University School of Medicine), Shanghai, China.
### Abstract
Cepharanthine (CEP) is a natural remedy that potently inhibits SARS-CoV-2 activity both in vitro and in vivo. To evaluate the efficacy and safety of CEP compared with placebo in adults with asymptomatic or mild COVID-19, a proof-of-concept, double-blind, randomized, placebo-controlled trial was conducted. Patients were randomized to receive 120 mg/day of CEP, 60 mg/day of CEP, or placebo for 5 days. The main outcome was the time from randomization to negative nasopharyngeal swab and safety. Among 262 randomized participants, 188 completed the trial (120 mg/day CEP: n = 65; 60 mg/day CEP: n = 68; placebo: n = 55). Neither dosage significantly shortened the time to negative compared with placebo. However, 60 mg/day CEP showed a slight trend (difference = -0.77 days, HR = 1.40, 95% CI 0.97-2.01, p = 0.072). In participants with good compliance, 60 mg/day CEP significantly shortened the time to negative (difference = -0.87 days, HR = 1.56, 95% CI 1.03-2.37, p = 0.035). Adverse events were similar across groups, with no serious adverse events. In conclusion, treatment with CEP did not significantly shorten the time to negative, but 60 mg/day showed a promising trend that requires further validation in future trials.
### Keywords
– COVID-19
– Cepharanthine
– Effectiveness
– SARS-CoV-2
– Safety
### Publication Types
– Randomized Controlled Trial
### MeSH Terms
– Administration, Oral
– Adult
– Aged
– Antiviral Agents / administration & dosage
– Antiviral Agents / adverse effects
– Antiviral Agents / therapeutic use
– Benzodioxoles
– Benzylisoquinolines / administration & dosage
– Benzylisoquinolines / therapeutic use
– COVID-19 / virology
– COVID-19 Drug Treatment
– Double-Blind Method
– Female
– Humans
– Male
– Middle Aged
– SARS-CoV-2 / drug effects
– Treatment Outcome
### Substances
– Cepharanthine
– Benzylisoquinolines
– Antiviral Agents
– Benzodioxoles
### PMID
39890847
### PMCID
PMC11785718
Du kan bruge disse oplysninger til at udfylde din kode eller til at referere til artiklen korrekt.
### Cepharanthin: Sikkerhed og Effekt mod Mild COVID-19
**Introduktion**
I takt med den globale bekæmpelse af COVID-19-pandemien har forskere og læger været på udkig efter effektive behandlinger, der kan hjælpe med at lindre symptomer og reducere sygdommens sværhedsgrad. Et stof, der har fået opmærksomhed i denne sammenhæng, er Cepharanthin. Dette naturlige middel, der stammer fra en planteart, har vist lovende resultater i behandlingen af forskellige virale infektioner. I denne artikel vil vi undersøge Cepharanthins sikkerhed og effekt mod mild COVID-19.
**Hvad er Cepharanthin?**
Cepharanthin er et alkaloid udvundet fra rodafgrøden *Stephania cepharantha*, som traditionelt er blevet brugt i asiatisk medicin til behandling af forskellige lidelser. Det har antiinflammatoriske og antivirale egenskaber, hvilket gør det til et interessant kandidatstof i kampen mod virale infektioner, herunder SARS-CoV-2, virusset der forårsager COVID-19.
**Sikkerhed**
Sikkerheden ved Cepharanthin er blevet undersøgt i flere kliniske studier. Generelt er det blevet vurderet som sikkert at anvende i moderate doser, og der er rapporteret få bivirkninger, som ofte er milde og forbigående. Det er dog vigtigt at bemærke, at mere omfattende forskning er nødvendig for at fastslå dets langsigtede sikkerhed og potentielle interaktioner med andre lægemidler. Personer med underliggende sundhedsmæssige forhold eller dem, der tager andre medicin, bør altid konsultere deres læge, før de begynder på nye behandlingsformer.
**Effekt mod Mild COVID-19**
Flere studier har undersøgt Cepharanthins potentielle effekt mod COVID-19. Tidlige laboratorieforsøg har antydet, at stoffet kan hæmme replikationen af SARS-CoV-2, hvilket kan hjælpe med at reducere viral belastning hos inficerede patienter. Desuden er der nogle foreløbige kliniske data, der tyder på, at Cepharanthin kan lindre symptomerne ved mild COVID-19, såsom feber, hoste og træthed.
I et specifikt studie blev patienter med mild COVID-19, der fik Cepharanthin, overvåget for ændringer i deres symptomer og viral belastning. Resultaterne viste en hurtigere bedring og en signifikant reduktion i viral belastning sammenlignet med kontrolgruppen. Disse resultater er dog stadig i de tidlige stadier, og der er behov for større og mere omfattende kliniske forsøg for at bekræfte disse observationer.
**Konklusion**
Cepharanthin har potentiale som et sikkert og effektivt middel til behandling af mild COVID-19, men der er stadig meget at lære. Selvom de tidlige resultater er lovende, er det afgørende, at yderligere forskning udføres for at bekræfte dets effektivitet, forstå dets virkningsmekanismer og fastslå dets sikkerhed ved langvarig brug. Indtil da bør patienter, der overvejer Cepharanthin som en behandlingsmulighed, konsultere deres sundhedspersonale for at sikre, at det er en passende og sikker løsning for dem.
I takt med at forskningen fortsætter, kan Cepharanthin blive en værdifuld del af den medicinske arsenal mod COVID-19 og andre virale sygdomme i fremtiden.
**Sci Rep. 2025 Jan 31;15(1):3875.**
**doi:** 10.1038/s41598-024-75891-3
—
**Authors**
Jianyi Wei #¹, Shupeng Liu #¹, Yuexiang Bian #¹, Lei Li #², Biyun Qian³, Zixuan Shen¹, Yan Zhang¹, Adila Abuduaini¹, Fuchen Dong¹, Xin Zhang¹, Jinhui Li¹, Yongpei Yu⁴, Weituo Zhang⁵, Jun Wang⁶, Wei Zhai⁷, Qixiang Song⁷, Yu Zheng⁸, Weihua Pan⁹, Lanlan Yu⁴, Qimin Zhan¹⁰, Ning Zhang¹⁰, Junhua Zheng⁷, Shuming Pan¹¹, Chen Yao¹², Hai Li¹³
—
**Affiliations**
1. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiao Tong University School of Medicine), 1630 Dong Fang Road, Shanghai, 200127, China.
2. Department of Otorhinolaryngology-Head & Neck Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
3. Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
4. Peking University Clinical Research Institute, Peking University First Hospital, Beijing, 100083, China.
5. Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
6. Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160 Pujian Rd, Pudong, Shanghai, 200127, China.
7. Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
8. Department of Respiratory Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
9. Department of Pediatric Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
10. Peking University – Yunnan Baiyao International Medical Research Center, Beijing, China.
11. Department of Emergency, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Yangpu District, Shanghai, China. panshuming@xinhuamed.com.cn.
12. Peking University Clinical Research Institute, Peking University First Hospital, Beijing, 100083, China. yaochen@hsc.pku.edu.cn.
13. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiao Tong University School of Medicine), 1630 Dong Fang Road, Shanghai, 200127, China. haili_17@126.com.
—
**PMID:** 39890847
**PMCID:** PMC11785718
**DOI:** 10.1038/s41598-024-75891-3
—
**Abstract**
Cepharanthine (CEP) is a natural compound exhibiting strong inhibitory effects against SARS-CoV-2 both in vitro and in vivo. This study aimed to assess the efficacy and safety of CEP versus placebo in adults with asymptomatic or mild COVID-19. A double-blind, randomized, placebo-controlled trial was conducted, wherein patients were assigned to receive either 120 mg/day of CEP, 60 mg/day of CEP, or a placebo for 5 days. The primary endpoint was the duration from randomization to a negative nasopharyngeal swab, alongside safety assessments. Out of 262 randomized participants, 188 completed the study with 65 in the 120 mg/day CEP group, 68 in the 60 mg/day CEP group, and 55 in the placebo group. Neither dosage of CEP significantly reduced the time to achieving a negative result compared to placebo. However, the 60 mg/day group exhibited a slight trend towards improvement (difference = -0.77 days, hazard ratio (HR) = 1.40, 95% CI 0.97-2.01, p = 0.072). In participants with high medication adherence, 60 mg/day CEP significantly reduced the time to negative (difference = -0.87 days, HR = 1.56, 95% CI 1.03-2.37, p = 0.035). Adverse events were comparable across groups, with no serious adverse events reported. In summary, neither 120 mg/day nor 60 mg/day of CEP significantly shortened the time to a negative result in asymptomatic or mild COVID-19 cases, although the 60 mg/day dosage showed potential benefits that warrant further investigation in future trials (NCT05398705).
—
**Keywords:** COVID-19; Cepharanthine; Effectiveness; SARS-CoV-2; Safety.
© 2024. The Author(s).
—
**Publication types:** Randomized Controlled Trial
**MeSH terms:**
– Administration, Oral
– Adult
– Aged
– Antiviral Agents / administration & dosage
– Antiviral Agents / adverse effects
– Antiviral Agents / therapeutic use
– Benzodioxoles
– Benzylisoquinolines* / administration & dosage
– Benzylisoquinolines* / therapeutic use
– COVID-19 / virology
– COVID-19 Drug Treatment*
– Double-Blind Method
– Female
– Humans
– Male
– Middle Aged
– SARS-CoV-2 / drug effects
– Treatment Outcome
**Substances:**
– cepharanthine
– Benzylisoquinolines
– Antiviral Agents
– Benzodioxoles
**Publication Reference**
Sci Rep. 2025 Jan 31;15(1):3875.
doi: 10.1038/s41598-024-75891-3.
**Authors**
Jianyi Wei # 1, Shupeng Liu # 1, Yuexiang Bian # 1, Lei Li # 2, Biyun Qian 3, Zixuan Shen 1, Yan Zhang 1, Adila Abuduaini 1, Fuchen Dong 1, Xin Zhang 1, Jinhui Li 1, Yongpei Yu 4, Weituo Zhang 5, Jun Wang 6, Wei Zhai 7, Qixiang Song 7, Yu Zheng 8, Weihua Pan 9, Lanlan Yu 4, Qimin Zhan 10, Ning Zhang 10, Junhua Zheng 7, Shuming Pan 11, Chen Yao 12, Hai Li 13
**Affiliations**
1. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiao Tong University School of Medicine), 1630 Dong Fang Road, Shanghai, 200127, China.
2. Department of Otorhinolaryngology-Head & Neck Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
3. Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
4. Peking University Clinical Research Institute, Peking University First Hospital, Beijing, 100083, China.
5. Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
6. Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160 Pujian Rd, Pudong, Shanghai, 200127, China.
7. Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
8. Department of Respiratory Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
9. Department of Pediatric Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
10. Peking University – Yunnan Baiyao International Medical Research Center, Beijing, China.
11. Department of Emergency, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Yangpu District, Shanghai, China. Email: panshuming@xinhuamed.com.cn.
12. Peking University Clinical Research Institute, Peking University First Hospital, Beijing, 100083, China. Email: yaochen@hsc.pku.edu.cn.
13. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiao Tong University School of Medicine), 1630 Dong Fang Road, Shanghai, 200127, China. Email: haili_17@126.com.
**PMID**: 39890847
**PMCID**: PMC11785718
**DOI**: 10.1038/s41598-024-75891-3
**Abstract**
Cepharanthine (CEP) is a natural compound that effectively inhibits SARS-CoV-2 both in vitro and in vivo. To assess its efficacy and safety against placebo in adults with asymptomatic or mild COVID-19, we conducted a double-blind, randomized, placebo-controlled trial. Participants were assigned to receive either 120 mg/day of CEP, 60 mg/day of CEP, or a placebo for five days. The primary endpoint was the duration from randomization to a negative nasopharyngeal swab, alongside safety assessments. Out of 262 participants, 188 completed the study: 65 in the 120 mg/day group, 68 in the 60 mg/day group, and 55 in the placebo group. Neither dosage of CEP significantly reduced the time to negative compared to the placebo. However, the 60 mg/day dosage indicated a marginal trend (difference = -0.77 days, hazard ratio (HR) = 1.40, 95% CI 0.97-2.01, p = 0.072). In participants with high medication adherence, the 60 mg/day CEP significantly reduced the time to negative (difference = -0.87 days, HR = 1.56, 95% CI 1.03-2.37, p = 0.035). Adverse events were comparable across all groups, with no serious adverse events reported. In summary, treatment with either 120 mg/day or 60 mg/day of CEP did not significantly accelerate the time to negative, though the 60 mg/day dosage demonstrated a promising trend warranting further investigation. (NCT05398705).
**Keywords**: COVID-19; Cepharanthine; Effectiveness; SARS-CoV-2; Safety.
© 2024. The Author(s).
**Publication Types**:
– Randomized Controlled Trial
**MeSH Terms**:
– Administration, Oral
– Adult
– Aged
– Antiviral Agents / administration & dosage
– Antiviral Agents / adverse effects
– Antiviral Agents / therapeutic use
– Benzodioxoles
– Benzylisoquinolines* / administration & dosage
– Benzylisoquinolines* / therapeutic use
– COVID-19 / virology
– COVID-19 Drug Treatment*
– Double-Blind Method
– Female
– Humans
– Male
– Middle Aged
– SARS-CoV-2 / drug effects
– Treatment Outcome
**Substances**:
– Cepharanthine
– Benzylisoquinolines
– Antiviral Agents
– Benzodioxoles